Drug Profile
Research programme: neurological disorder therapeutics - Aequus Pharmaceuticals/CannaRoyalty
Alternative Names: Cannabis-based therapies - Aequus Pharmaceuticals/CannaRoyaltyLatest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Aequus Pharmaceuticals
- Class Cannabinoids
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Neurological-disorders in Canada
- 11 Jan 2018 Aequus Pharmaceuticals and CannaRoyalty agree to co-promote and co-develop cannabis-based therapies in Canada for Neurological disorders
- 11 Jan 2018 Early research in Neurological disorders in Canada